Clinical Value of Platelet Count and Platelet-Lymphocyte Ratio (PLR) in Patients with Thyroid Malignancy
DOI:
https://doi.org/10.35790/ecl.v13i2.61266Abstract
Abstract: Platelet count index may be used as useful clinical markers in the differential diagnosis of benign and malignant thyroid disorders. Platelet–lymphocyte ratio (PLR) has recently been introduced as prognostic markers of thyroid cancer and strong inflammatory markers. This study aimed to evaluate the clinical value of the platelet count and PLR in thyroid malignancy. Subjects were 61 patients with thyroid nodule who were followed up at the General Surgery Clinic of Prof. Dr. R. D. Kandou Hospital, and underwent ultrasound examination, FNAB, thyroidectomy, and histopathological examination. Categorical scale data were described through frequencies and percentages, while numerical scale data were presented in the form of min, max, mean and standard deviation. The results showed that thyroid nodules predominantly occurred in females (60.65%); 25 of 37 patients (67.57%) of whom had malignancy. Meanwhile, of 24 male patients (39.3%), there were 17 patients (38.64%) who had thyroid malignancy. In this study, the platelet count and PLR were no significantly higher in patients with papillary thyroid malignancy than in those with non-malignancy. As many as 42 patients (68.85%) with thyroid malignancy had normal platelet count and as many as 44 patients (72.13%) had low PLR; these results were the same with non-malignancy thyroid. In conclusion, thyroid malignancy is predominantly comprising between age 40-59 years old, dominated by females. Laboratory results shows that the majority have normal platelet count and low platelet–lymphocyte ratio. Further research and patient follow-up are needed to evaluate the platelets and platelet–lymphocyte ratio in patients with thyroid malignancy.
Keywords: platelet count, platelet-lymphocyte ratio, thyroid malignancy
References
Ari A, Gunver F. Comparison of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with thyroiditis and papillary tumors. Journal of International Medical Research. 2019;47(5):2077–83. Doi: 10.1177/0300060519838392
Jiang C, Wu Y, Huang J, Wang Y, Cong H. Clinical value of complete blood count ratio in benign and malignant thyroid diseases. Cancer Epidemiol. 2024;92:102636. Available from: https://doi.org/10.1016/j.canep.2024.102636
Kalbuningwang GG, Susilo DH, Wibowo MD, Sahudi. Correlation of platelet-lymphocyte ratio towards the incidence of follicular thyroid carcinoma. International Journal of Research and Review. 2021;8(9):36-42. Doi: https://doi.org/10.52403/ijrr.20210907
Do BA, Payne RJ, Batianelli M, Mlynarek AM, Tamilia M, Hier M, et al. Is age associated with risk of malignancy in thyroid cancer? Otolaryngol Head Neck Surg. 2014;151(5):746-50. Doi: 10.1177/0194599814547503
Haymart MR. Understanding the relationship between age and thyroid cancer. The Oncologist. 2019;14(3):216-21. Available from: https://doi.org/10.1634/theoncologist.2008-0194
Baldane S, Ipeksi SH, Sozen M, Kebepcilar L. Mean platelet volume could be possible biomarker for papillary thyroid carcinoma. Asian PAC J Cancer. 2015;Prev16:2671-4. Doi: 10.7314/apjcp.2015.16.7.2671
Rianto BUD, Nugraha RP, Indrasari SR Raditya AE. The difference platelet lymphocyte ratio and thrombocyte volume between benign compared to carcinoma thyroid gland. Biomed J Sci Tech Res. 2019;19(2):14138–42. Doi: 10.26717/BJSTR.2019.19.003261
Martin S, Mustata T, Enache O, Ion O, Chifulescu A, Sirbu A, et al. Platelet activation and inflammation in patients with papillary thyroid cancer. Diagnostics. 2021;11(11):1959. Available from: https://doi.org/10.3390/diagnostics11111959
Misrak S, Kucuk S. Platelet levels and neutrophil to lymphocyte ratio in thyroid nodules with and without cancer diagnosis. Medicine Science International Medical Journal. 2020;9(1):16-20. Doi: 10.5455/medscience.2019.08.9125
Atak Tel. Kahveci G. Bilgin S. Kurtkulagi O Kosekli M. Platelet to lymphocyte ratio in differentiation of benign and malignant thyroid nodules. J. -ebr. 2021;4 (2):148-53. Doi: 10.30714/j-ebr.2021267978
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nico Lumintang, Sherly Tandililing, Elisse S. Susilo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
